Clinical Trials Directory

Trials / Unknown

UnknownNCT01676168

To Study Gene Expression of Postburn Hypertrophic Scar

Status
Unknown
Phase
Study type
Observational
Enrollment
30 (estimated)
Sponsor
National Taiwan University Hospital · Academic / Other
Sex
All
Age
20 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Aim: To compare the gene expression of postburn hypertrophic scar with normal skin.

Detailed description

Background: Postburn hypertrophic scar (HS) remains a challenging problem. Although varied clinical therapeutic methods have been used, none of them has been widely accepted as a standard care. As hypertrophic scar is hereditary, gene therapy can be a potential tool for scar treatment. To investigate the correlation between the clinical presentation of the hypertrophic scar and its gene expression, we propose an analysis of gene expression in the hypertrophic scar using DNA microarray and Real-Time Quantitative PCR. The study result may form the base of clinical treatment. Methods and Materials: Thirty scar patients requiring surgical treatment in NTUH burn center will be enrolled into the study. Inclusion criteria: (1) Age between 20 and 80 (2) Patients with postburn hypertrophic scar require surgical treatment. 1. Hypertrophic scar and normal skin collection: Under Clinical Trial Informed Consent of Research Ethic Committee, scar and normal skin specimen of 1x1cm2 each will be collected and transported to tissue bank with a vacuum low temperature container. The specimen will be kept in a -80℃ refrigerator. 2. RNA extraction from skin tissue: The RNA extraction will be performed using kit available in the market. Spectrophotometer and gel electrophoresis will be used to measure the purity and concentration of RNA. 3. Gene expression analysis: DNA microarray and Real-Time Quantitative PCR will be used to analyze RNA expression of hypertrophic scar and normal skin. Statistics: Student's t-test will be used to compare statistically gene expression between hypertrophic scar and normal skin. P \< 0.05 will be considered as statistical significance.

Conditions

Timeline

Start date
2012-07-01
Primary completion
2013-07-01
First posted
2012-08-30
Last updated
2012-08-30

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT01676168. Inclusion in this directory is not an endorsement.